SCI & TECH● LOWSep 11 · Sep 11, 2026, 12:59 PM
Exelixis zanzalintinib NDA review extended three months by FDA
Seeking Alpha Tech · north america
The FDA has extended its review period for Exelixis' zanzalintinib NDA by three months. This indicates a longer assessment timeframe for the new drug application.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Sci & Tech
SCI & TECH23m ago"Mommy and daddy" play nice: Apple and Meta team up to bring open-source Muse to MacsAxiosSCI & TECH23m agoApple and Meta team up to make Muse AI model run on Mac computersCNBCSCI & TECH26m agoSony unveils high-end Walkman with gold-plated copper chassisSeeking Alpha TechSCI & TECH38m agoInside the race between Elon Musk and Jeff Bezos for control of outer spaceNPR News